ABSTRACT
The changes of cortical structure in Alzheimer’s disease (AD) and frontotemporal dementia (FTD) are usually described in terms of atrophy. However, neurodegenerative diseases may also affect the complexity of cortical shape, such as the fractal dimension of the brain surface. Thirty-two people with symptomatic AD-pathology (clinically probable AD, n=18, and amyloid-positive mild cognitive impairment, n=14), 24 with FTD and 28 healthy controls underwent high-resolution 3T structural brain MRI. Using surface-based morphometry, we created vertex-wise cortical thickness and fractal dimension maps for group comparisons and correlations with cognitive measures in AD and FTD. In addition to the well-established pattern of cortical thinning encompassing temporoparietal regions in AD and frontotemporal areas in FTD (FDR p< 0.05), we observed reductions of fractal dimension specifically involving precuneus and posterior cingulate for AD and orbitofrontal cortex and insula for FTD. Correlational analyses between fractal dimension and cognition showed that these regions were particularly vulnerable with regards to memory and language impairment in both AD and FTD. This study demonstrates a distinct pattern of fractal dimension impairment and correlation with cognition. Further studies are required to assess cortical complexity measures at earlier disease stages (e.g. in prodromal/ asymptomatic carriers of FTD-related gene mutations) to assess whether fractal dimension represents a sensitive imaging marker for prevention and diagnostic strategies.
Competing Interest Statement
J. B. Rowe serves as editor to Brain, has been a consultant for Asceneuron and Syncona, and has received academic grant funding from AZ-MedImmune, Janssen, and Lilly, unrelated to this study. J. T. O’Brien has served as deputy editor of International Psychogeriatrics, received grant support from Avid (Lilly), and served as a consultant for Avid and GE Healthcare, all for matters not related to the current study.
Funding Statement
This study was funded by the National Institute for Health Research (NIHR, RG64473) Cambridge Biomedical Research Centre and Biomedical Research Unit in Dementia, the Wellcome Trust (JBR 103838), the Medical Research Council of Cognition and Brain Sciences Unit, Cambridge (MC-A060-5PQ30) and Cambridge Center for Parkinson Plus.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.
